Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis

Pediatrics

Volumn 125, Issue 2, 2010, Pages

  Payne, Daniel C ^a   Edwards, Kathryn M ^b   Bowen, Michael D ^a   Keckley, Erin ^b   Peters, Jody ^b   Esona, Mathew D ^a   Teel, Elizabeth N ^a   Kent, Diane ^b   Parashar, Umesh D ^a   Gentsch, Jon R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute gastroenteritis; Horizontal transmission; New Vaccine Surveillance Network; NVSN; Reassortant; RotaTeq; Rotavirus; Rotavirus vaccine; Shedding; Sibling transmission; WC3

Indexed keywords

ONDANSETRON; ROTAVIRUS VACCINE;

ARTICLE; COLON INTUSSUSCEPTION; ELECTRON MICROSCOPY; EMERGENCY CARE; EMERGENCY WARD; ENZYME IMMUNOASSAY; GASTROENTERITIS; GENOTYPE; HUMAN; IMMUNIZATION; NAUSEA AND VOMITING; OPTICAL DENSITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIBLING; VACCINATION; VIRULENCE; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIGENS, VIRAL; CAPSID PROTEINS; CHILD, PRESCHOOL; FECES; GASTROENTERITIS; HUMANS; INFANT; MALE; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SIBLINGS; VACCINES, ATTENUATED; VIRULENCE; VIRUS REPLICATION;

EID: 76049128237     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-1901     Document Type: Article

References (29)

1. RotaTeq (rotavirus vaccine, live, oral, pentavalent) [package insert]. Rockville, MD: Merck; 2006
2. Parashar UD, Alexander JP, Glass RI; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children. MMWR Recomm Rep. 2006;55(RR-12):1-13
3. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent humanbovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33
4. Vesikari T, Itzler R, Matson DO, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis. 2007;11(suppl 2):S29 -S35
5. Belongia E, Irving S, Shui I, et al. Rapid cycle analysis of pentavalent rotavirus (RotaTeq) vaccine safety in the Vaccine Safety Datalink population: preliminary results. Paper presented at: meeting of the Advisory Committee on Immunization Practices; June 25, 2008; Atlanta, GA
6. World Health Organization. Global Advisory Committee on Vaccine Safety, 17-18 December 2008. Wkly Epidemiol Rec. 2009; 84(5):37- 40
7. Boom JA. Effectiveness of pentavalent rotavirus vaccine in United States clinical practice. Paper presented at: meeting of the Advisory Committee on Immunization Practices; October 23, 2008; Atlanta, GA
8. Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity: United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep. 2008;57(25):697-700
9. Clark HF, Lawley D, Mallette LA, et al. Decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol. 2009;16(3):382-386
10. Payne DC, Staat MA, Edwards KM, et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics. 2008;122(6): 1235-1243
11. Das BK, Gentsch JR, Cicirello HG, et al. Characterization of rotavirus strains from newborns in New Delhi, India. J Clin Microbiol. 1994;32(7):1820 -1822
12. Freeman MM, Kerin T, Hull J, et al. Enhancement of detection and quantification of rotavirus in stool using a modified real-time RT-PCR assay. J Med Virol. 2008;80(8): 1489 -1496
13. Gentsch JR, Glass RI, Woods P, et al. Identifi-cation of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol. 1992;30(6):1365-1373
14. Esona MD, Steele D, Kerin TK, et al. Determination of the G and P types of previously non-typeable rotavirus strains from the African Rotavirus Network from 1996 -2004: identification of unusual G types. J Infect Dis. 2010; In press
15. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr. 2004;144(2):184 -190
16. Clark HF, Borian FE, Bell LM, et al. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype I rotavirus season. J Infect Dis. 1988; 158(3):570 -587
17. Clark HF, Burke CJ, Volkin DB, et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J. 2003; 22(10):914 -920
18. Block SL, Vesikari T, Goveia MG, et al; Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119(1):11-18
19. Yen C, Jakob K, Peckham X, et al. Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. Paper presented at: annual meeting of the Pediatric Academic Societies; May 4, 2009; Baltimore, MD
20. Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol. 2007;5(7):529 -539
21. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 2008;8(10):642- 649
22. McCormack PL, Keam SJ, Bernstein DI, et al. Rotavirus vaccine RIX4414 (Rotarix): a review of itsuseintheprevention of rotavirus gastroenteritis. Paediatr Drugs. 2009;11(1):75-88
23. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis. 2005; 192(suppl 1):S6 -S16
24. Han HH. Summary of human rotavirus vaccine Rotarix: safety and efficacy trials. Paper presented at: the Vaccines for Enteric Disease Conference; September 10, 2009; Malaga, Spain
25. Otsuka T, Gomi Y, Inoue N, et al. Transmission of varicella vaccine virus, Japan. Emerg Infect Dis. 2009;15:1702-1703
26. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses: worldwide, January 2008 -June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(36): 1002-1006
27. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696 -1701
28. Cortese MM, Parashar UD; Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWRRecomm Rep. 2009;58(RR-2):1-26
29. Patel NC, Hertel PM, Estes MK, et. al. Vaccineacquired rotavirus infection in two infants with severe combined immunodeficiency. Paper presented at: meeting of the American Academy of Allergy Asthma & Immunology. March 17, 2009; Washington, DC